J4ams21 Jan 2021 16:59
Would you mind if I trade marked the Richnob name?
For clarity, accepting what sagetrade has already said, producing a sub standard test would not make sense if you are looking at the world market. This is what is available and if we have had to wait when the pandemic is still increasing, then I am unclear why there is a need to rush. I think Avacta are looking beyond the UK as well as supporting it initially.
In addition, the saliva test is being progressed in alongside a nasal test and hasn't disappeared.
BAMS is already available via Adeptrix for research purposes at $1200 per kit and, like sagetrade, I think is part of other things now.
Please feel free to filter me.